MYCOFNoveris Health Sciences Inc.
This is the year Noveris Health Sciences Inc. has to prove it’s more than a name on a balance sheet. The next catalyst — the Clinical Pipeline & R&D Update on October 15 — is the first real test, with the stock anchored at $0.73 and a bull target of $1.00, a bear fallback of $0.60, and a lean toward the bear. If it can hold the anchor, the next step is the Q3 2026 Earnings Release on November 26, where the stock is priced at $0.60, with a bull target of $0.86 and a bear of $0.45. The path is clear, the stakes are high, and the outcome will say a lot about whether this company is a real player or just another ghost in the medical-pharma space.
The schedule
- Thu15Oct
- Thu26Nov
- Wed20Jan
- Thu25Mar
Past
- Fri4Sep
Actual outcome: Mixed
The stock remained flat following the AGM, with no significant price movement toward either the bull target of $0.95 or the bear floor of $0.65. The event focused on shareholder votes and strategic updates, but no major catalysts emerged to drive material price action. The lack of clear directional movement suggests the market remained neutral on the company's near-term prospects.
Annual general meeting with potential shareholder votes and strategic updates.
- Thu27Aug
Actual outcome: Mixed
The company reported an EPS actual of -0.1, matching the estimate, with no significant beat or miss. However, the stock remained flat due to positive developments such as the USPTO Notice of Allowance for a patent and a work order with API, which signaled potential growth and operational progress. These strategic advancements likely offset the neutral earnings report, resulting in a mixed price reaction.
The upcoming Q2 print serves as the first major update following Noveris's apparent balance sheet restructuring in early 2026. Investors will look for commentary on the newly raised cash runway and operational priorities.
